Shenzhen Kaili Biomedical Technology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
I. Reasons for Notifying Creditors
On March 17, 2026, the Company held the 14th meeting of the 4th Board of Directors and on April 3, 2026, held the first extraordinary general meeting of shareholders in 2026, where the proposal for the share buyback plan was approved. The Company will use its own or self-raised funds (including funds from special loans for share buybacks) to repurchase shares through centralized bidding, all of which will be used for cancellation and reduction of registered capital. The total amount for the buyback will not be less than RMB 100 million (inclusive) and not more than RMB 200 million (inclusive), with the specific total amount determined by the actual funds used upon completion of the buyback period or implementation.